WuXi Biologics has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will house the company’s 12th drug substance manufacturing facility.
 
This new integrated manufacturing center will include drug development and commercial manufacturing facilities with initial bioreactor capacity of 48,000L. As the first biologics company in China passing both U.S. FDA and EMA GMP inspections, WuXi Biologics will apply its expertise as well as an established quality system that conforms to the highest international standards at this new integrated manufacturing center. The new site will enable more global partners, create more jobs for local talents, stimulate high growth of the biologics industry in Chengdu as well as accelerate the biologics ecosystem in Southwest China.
 
“We are quite excited to commence this new integrated manufacturing center, the largest biologics manufacturing facility in Southwest China,” said Chris Chen, chief executive officer, WuXi Biologics. “Supported by 205 ongoing biologics projects using WuXi Biologics’ open-access and proprietary platforms as well as our unique manufacturing paradigm of ‘Global Dual Sourcing within WuXi Bio,’ we will continue to expand manufacturing capacity, based on our portfolio needs, to provide a robust and premier global supply chain that can enable our partners and benefit patients worldwide.”